Osteoporosis in men and women

Consensus Development Conference, 1993, Diagnosis, prophylaxis, and treatment of osteoporosis, Am J Med, 94, 646, 10.1016/0002-9343(93)90218-E National Osteoporosis Foundation, 2006 Campion, 2003, Osteoporosis in men, Am Fam Phys, 67, 1521 Scane, 1993, Osteoporosis in men, Baillieres Clin Rheumatol, 7, 589, 10.1016/S0950-3579(05)80081-0 Kamel, 2005, Male osteoporosis: New trends in diagnosis and therapy, Drugs Aging, 22, 741, 10.2165/00002512-200522090-00003 van der Klift, 2002, Bone mineral density and mortality in elderly men and women: The Rotterdam Study, Bone, 30, 643, 10.1016/S8756-3282(02)00670-1 Sigurdsson, 2006, Increasing sex difference in bone strength in old age: The Age, Gene/Environment Susceptibility-Reykjavik study (AGESREYKJAVIK), Bone, 39, 644, 10.1016/j.bone.2006.03.020 van der Klift, 2005, Assessment of fracture risk: Who should be treated for osteoporosis?, Best Pract Res Clin Rheumatol, 19, 937, 10.1016/j.berh.2005.06.001 van der Klift, 2002, The incidence of vertebral fractures in men and women: The Rotterdam Study, J Bone Miner Res, 17, 1051, 10.1359/jbmr.2002.17.6.1051 Marshall, 1996, Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures, BMJ, 312, 1254, 10.1136/bmj.312.7041.1254 van der Klift, 2004, Risk factors for incident vertebral fractures in men and women: The Rotterdam Study, J Bone Miner Res, 19, 1172, 10.1359/JBMR.040215 Klotzbuecher, 2000, Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis, J Bone Miner Res, 15, 721, 10.1359/jbmr.2000.15.4.721 Lim, 2004, Body composition changes with age have gender-specific impacts on bone mineral density, Bone, 35, 792, 10.1016/j.bone.2004.05.016 Goderie-Plomp, 2004, Endogenous sex hormones, sex hormone-binding globulin, and the risk of incident vertebral fractures in elderly men and women: The Rotterdam Study, J Clin Endocrinol Metab, 89, 3261, 10.1210/jc.2002-022041 World Health Organization, 2006, Prevention and management of osteoporosis US Preventive Services Task Force, 2002 National Osteoporosis Foundation, 2003 AACE, 2003, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 Edition, with selected updates for 2003, Endocr Prac, 9, 545 Management of osteoporosis in postmenopausal women, 2006, 2006 Position statement of the North American Menopause Society, Menopause, 13, 340, 10.1097/01.gme.0000222475.93345.b3 2007 The Writing Group for the ISCD Position Development Conference, 2004, Diagnosis of osteoporosis in men, premenopausal women and children, J Clin Densitom, 7, 17, 10.1385/JCD:7:1:17 Binkley, 2006, Official positions of the International Society for Clinical Densitometry and executive summary of the 2005 Position Development Conference, J Clin Densitom, 9, 4, 10.1016/j.jocd.2006.05.002 Canadian Panel of the ISCD, 2004, Canadian physician pocket guide to BMD testing, International Society for Clinical Densitometry Black, 1996, Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures, Lancet, 348, 1535, 10.1016/S0140-6736(96)07088-2 Cummings, 1998, Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures, JAMA, 280, 2077, 10.1001/jama.280.24.2077 Black, 2000, Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial, J Clin Endocrinol Metab, 85, 4118, 10.1210/jc.85.11.4118 Orwoll, 2000, Alendronate for the treatment of osteoporosis in men, N Engl J Med, 343, 604, 10.1056/NEJM200008313430902 Ringe, 2001, Alendronate treatment of established primary osteoporosis in men: Results of a 2-year prospective study, J Clin Endocrinol Metab, 86, 5252, 10.1210/jc.86.11.5252 Ringe, 2004, Alendronate treatment of established primary osteoporosis in men: 3-Year results of a prospective, comparative, two-arm study, Rheumatol Int, 24, 110, 10.1007/s00296-003-0388-y Iwamoto, 2007, Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosis, Clin Rheumatol, 26, 161, 10.1007/s10067-006-0252-z Sorensen, 2003, Long-term efficacy of risedronate: A 5-year placebo-controlled clinical experience, Bone, 32, 120, 10.1016/S8756-3282(02)00946-8 Reginster, 2000, Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis, Osteoporos Int, 11, 83, 10.1007/s001980050010 Harris, 1999, Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial, JAMA, 282, 1344, 10.1001/jama.282.14.1344 McClung, 2001, Effect of risedronate on the risk of hip fracture in elderly women: HIP Intervention Program Study Group, N Engl J Med, 344, 333, 10.1056/NEJM200102013440503 Ringe, 2006, Efficacy of risedronate in men with primary and secondary osteoporosis: Results of a 1-year study, Rheumatol Int, 26, 427, 10.1007/s00296-005-0004-4 Sato, 2005, Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke, Arch Intern Med, 165, 1743, 10.1001/archinte.165.15.1743 Sato, 2005, Risedronate therapy for prevention of hip fracture after stroke in elderly women, Neurology, 64, 811, 10.1212/01.WNL.0000152871.65027.76 Green, 2004, Bisphosphonates: Preclinical review, Oncologist, 3, 10.1634/theoncologist.9-90004-3 Bonnick, 2006, Comparison of weekly treatment of postmenopausal osteoporosis with alendronate vs. risedronate over two years, J Clin Endocrinol Metab, 91, 2631, 10.1210/jc.2005-2602 Dunford, 2001, Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates, J Pharmacol Exp Ther, 296, 235 Neer, 2001, Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis, N Engl J Med, 344, 1434, 10.1056/NEJM200105103441904 Orwoll, 2003, The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis, J Bone Miner Res, 18, 9, 10.1359/jbmr.2003.18.1.9 Black, 2003, The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis, N Engl J Med, 349, 1207, 10.1056/NEJMoa031975 Finkelstein, 2003, The effects of parathyroid hormone, alendronate, or both in men with osteoporosis, N Engl J Med, 349, 1216, 10.1056/NEJMoa035725 Black, 2005, One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis, N Engl J Med, 353, 555, 10.1056/NEJMoa050336 Lindsay, 2004, Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis, Arch Intern Med, 164, 2024, 10.1001/archinte.164.18.2024 Kurland, 2004, The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone (1–34)], Osteoporos Int, 15, 992, 10.1007/s00198-004-1636-z